-
Infectious disease company Durata Therapeutics Inc. (NASDAQ:DRTX) raised $50.1 million through the sale of 7.2 million shares at $7 in a follow-on underwritten by BofA Merrill Lynch; Credit Suisse; Jefferies; JMP …
Published on 4/12/2013
-
Infectious disease company Chimerix Inc. (NASDAQ:CMRX) and hypertriglyceridemia company Omthera Pharmaceuticals Inc. (NASDAQ:OMTH) both priced IPOs on Thursday. Chimerix priced in the middle of its proposed range and …
Published on 4/11/2013
-
President Obama's FY14 budget proposal would lead to a projected $371 billion in Medicare savings over 10 years in part through increased rebates and discounts from drug companies. Obama's budget, which was submitted to…
Published on 4/10/2013
-
If comments from senators at a Senate Finance Committee hearing to discuss the confirmation of CMS's Acting Administrator Marilyn Tavenner are any indication, the agency appears on track to have a confirmed …
Published on 4/9/2013
-
The Global Health Innovative Technology (GHIT) Fund debuted on Monday to advance R&D for therapeutics, vaccines and diagnostics for infectious diseases in the developing world. The public-private partnership was …
Published on 4/8/2013
-
A judge in the U.S. District Court for the Eastern District of New York ordered FDA on Friday to make emergency contraceptives available within 30 days "without a prescription and without point-of-sale or age …
Published on 4/5/2013
-
New healthcare VC firm Lightstone Ventures is seeking to raise up to $250 million for its first fund, according to an SEC filling. The firm was formed in 2012 by the general partners and other members of the life …
Published on 4/4/2013
-
The MedImmune LLC biologics unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired cardiovascular company AlphaCore Pharma (Ann Arbor, Mich.). Details of the deal were not disclosed. AlphaCore is developing ACP-501, a …
Published on 4/3/2013
-
Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Eliquis apixaban from Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) has "significant" additional benefit to prevent …
Published on 4/2/2013
-
India's Supreme Court upheld a 2009 ruling by India's Intellectual Property Appellate Board (IPAB) denying a patent for cancer drug Glivec imatinib from Novartis AG (NYSE:NVS; SIX:NOVN). In its decision, the Supreme …
Published on 4/1/2013
-
FDA approved an NDA from Johnson & Johnson (NYSE:JNJ) for Invokana canagliflozin to improve glycemic control in adults with Type II diabetes. The pharma plans to launch the product next week. J&J told BioCentury that …
Published on 3/29/2013
-
Edison Pharmaceuticals Inc. (Mountain View, Calif.) granted Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) exclusive rights to develop and commercialize EPI-743 and EPI-589 in Japan. Edison, which retains …
Published on 3/28/2013
-
FDA approved Tecfidera dimethyl fumarate (formerly BG-12) from Biogen Idec Inc. (NASDAQ:BIIB) to treat adults with relapsing forms of multiple sclerosis. Tecfidera's label includes a warning about lymphopenia and …
Published on 3/27/2013
-
Ziopharm Oncology Inc. (NASDAQ:ZIOP) fell $3.31 (65%) to $1.82 on Tuesday after the company discontinued development of Zymafos palifosfamide as first-line treatment of soft tissue sarcoma (STS). The move came after IV …
Published on 3/26/2013
-
Healthcare VC firm Third Rock Ventures closed its third fund at $516 million. The firm said it plans to use the fund to launch or invest in up to 16 new companies. Third Rock closed its first fund with $378 million in …
Published on 3/25/2013
-
EMA's CHMP recommended approval of two relapsing-remitting multiple sclerosis (RRMS) therapies on Friday: Tecfidera dimethyl fumarate (BG-12) from Biogen Idec Inc. (NASDAQ:BIIB) and Aubagio teriflunomide from Sanofi (…
Published on 3/22/2013
-
AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered with Moderna Therapeutics Inc. (Cambridge, Mass.) to discover, develop and commercialize messenger RNA therapeutics to treat cardiovascular, metabolic and renal diseases, as…
Published on 3/21/2013
-
Both Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) and Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) priced IPOs on Wednesday. The former priced below its proposed range but sold more shares, while the latter sold the …
Published on 3/20/2013
-
Comments from the U.S. Supreme Court Justices at Tuesday's oral arguments for Mutual Pharmaceutical Co. v. Bartlett suggest that if the Justices side with lower courts, both branded and generics companies could be …
Published on 3/19/2013
-
AstraZeneca plc (LSE:AZN; NYSE:AZN) announced a restructuring on Monday that will see the pharma's headquarters move to Cambridge, U.K., from London and will consolidate its small molecule and biologics R&D activities …
Published on 3/18/2013
-
Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that Type II diabetes drug Forxiga dapagliflozin from Bristol-Myers Squibb Co. (NYSE:BMY) and AstraZeneca …
Published on 3/15/2013
-
EMA said it plans to have the capabilities to analyze raw data during the review of MAAs by the end of 2015, according to the agency's 2013 work program. Currently, companies provide an analysis of raw data in MAA …
Published on 3/14/2013
-
The budget bill released by the Senate Appropriations Committee on Tuesday would increase FDA's budget authority for the remainder of FY13 by $23.9 million over FY12, excluding the impact of sequestration, according to …
Published on 3/13/2013
-
The Senate Appropriations Committee released on Tuesday a budget bill that would give FDA authority to spend new and increased user fees for the remainder of FY13. The Senate bill authorizes FDA to collect and spend two…
Published on 3/12/2013
-
AbbVie Inc. (NYSE:ABBV) said it filed two suits against EMA in January in the European Union General Court "seeking to protect AbbVie's confidential and commercially-sensitive information" for autoimmune drug Humira …
Published on 3/11/2013